Juvenile mesenchymal stem cells are prepared into a saline bag and given to the child through a simple saline drip. The stem cells will go to the areas they are needed. In many cases they will home in on the intestinal track and brain. Here, they will secrete cytokines and growth factors. This will signal the resident stem cells to proliferate, causing tissue regeneration. The child can receive multiple doses over a period of time. Duke University in the United States has successfully used cord blood stem cell to treat Autistic children with very solid clinical results. This is published peer reviewed scientific evidence of how adult stem cell can safely help your child.
Chez M1,2, Lepage C1,2, Parise C2, Dang-Chu A2, Hankins A2, Carroll M3.
1- Pediatric Neuroscience, Sacramento, California, USA.
2- Sutter Institute for Medical Research (SIMR), Sacramento, California, USA.
3- Bone Marrow Transplant, Sutter Medical Group, Sacramento, California, USA.
The aim of this exploratory study was to assess the safety and clinical effects of autologous umbilical cord blood (AUCB) infusion in children with idiopathic autism spectrum disorder (ASD). Twenty-nine children 2 to 6 years of age with a confirmed diagnosis of ASD participated in this randomized, blinded, placebo-controlled, crossover trial. Participants were randomized to receive AUCB or placebo, evaluated at baseline, 12, and 24 weeks, received the opposite infusion, then re-evaluated at the same time points. Evaluations included assessments of safety, Expressive One Word Picture Vocabulary Test, 4th edition, Receptive One Word Picture Vocabulary Test, 4th edition, Clinical Global Impression, Stanford-Binet Fluid Reasoning and Knowledge, and the Vineland Adaptive Behavior and Socialization Subscales. Generalized linear models were used to assess the effects of the response variables at the 12- and 24-week time periods under each condition (AUCB, placebo). There were no serious adverse events. There were trends toward improvement, particularly in socialization, but there were no statistically significant differences for any endpoints. The results of this study suggest that autologous umbilical cord infusions are safe for children with ASD. Tightly controlled trials are necessary to further progress the study of AUCB for autism. Stem Cells Translational Medicine 2018;7:333-341.
Stem Cells Transl Med. 2017 May;6(5):1332-1339. doi: 10.1002/sctm.16-0474. Epub 2017 Apr 5.
Dawson G1, Sun JM2, Davlantis KS1, Murias M1,3, Franz L1, Troy J2, Simmons R2, Sabatos-DeVito M1, Durham R2, Kurtzberg J2.
1- Duke Center for Autism and Brain Development, Duke University Medical Center.
2- Robertson Clinical and Translational Cell Therapy Program, Duke University Medical Center.
3- Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, USA.
Despite advances in early diagnosis and behavioral therapies, more effective treatments for children with autism spectrum disorder (ASD) are needed. We hypothesized that umbilical cord blood-derived cell therapies may have potential in alleviating ASD symptoms by modulating inflammatory processes in the brain. Accordingly, we conducted a phase I, open-label trial to assess the safety and feasibility of a single intravenous infusion of autologous umbilical cord blood, as well as sensitivity to change in several ASD assessment tools, to determine suitable endpoints for future trials. Twenty-five children, median age 4.6 years (range 2.26-5.97), with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit, were enrolled. Children were evaluated with a battery of behavioral and functional tests immediately prior to cord blood infusion (baseline) and 6 and 12 months later. Assessment of adverse events across the 12-month period indicated that the treatment was safe and well tolerated. Significant improvements in children’s behavior were observed on parent-report measures of social communication skills and autism symptoms, clinician ratings of overall autism symptom severity and degree of improvement, standardized measures of expressive vocabulary, and objective eye-tracking measures of children’s attention to social stimuli, indicating that these measures may be useful endpoints in future studies. Behavioral improvements were observed during the first 6 months after infusion and were greater in children with higher baseline nonverbal intelligence quotients. These data will serve as the basis for future studies to determine the efficacy of umbilical cord blood infusions in children with ASD. Stem Cells Translational Medicine 2017;6:1332-1339.